BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma-Reference-Cited by-同舟云学术

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma

Published:2013-12-06 Issue:7 Volume:27 Page:1028-1034
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Goeppert Benjamin,Frauenschuh Lena,Renner Marcus,Roessler Stephanie,Stenzinger Albrecht,Klauschen Frederick,Warth Arne,Vogel Monika Nadja,Mehrabi Arianeb,Hafezi Mohammadreza,Boehmer Katja,von Deimling Andreas,Schirmacher Peter,Weichert Wilko,Capper David

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2013206.pdf

Reference38 articles.

1. Blechacz B, Komuta M, Roskams T et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011;8:512–522.

2. Hezel AF, Deshpande V, Zhu AX . Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28:3531–3540.

3. Schindler G, Capper D, Meyer J et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397–405.

4. Michaloglou C, Vredeveld LC, Mooi WJ et al. BRAF(E600) in benign and malignant human tumours. Oncogene 2008;27:877–895.

5. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–954.

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The biliary tree musketeers: cholangiocarcinoma – one name for all, but at least three different diseases with distinct targets;Surgical and Experimental Pathology;2024-08-20

2. Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches;Cancers;2024-08-20

3. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers;Critical Reviews in Oncology/Hematology;2024-07

4. Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives;Future Oncology;2024-05-30

5. Advances in Immunooncology and Precision Medicine in Cholangiocarcinoma;Digestive Disease Interventions;2024-05-15